CLEVELAND, Jan. 31, 2022 /PRNewswire/ -- NovelMed Therapeutics announced today that its Investigational New Drug Application (IND) to initiate clinical trials of its NM8074 biologic has been cleared ...

Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...

A first-in-class oral inhibitor of the alternative complement pathway that drives the pathogenesis of primary glomerulonephritis, iptacopan (LNP023, Novartis), is showing early promise as the first ...

...CR2-fH substantially reduced disease activity and joint damage... An inhibitor of the alternative pathway (AP) of complement activation reduces clinical disease activity and joint damage in an ...

Cedars-Sinai investigators have identified a genetic variant that increases people’s risk of developing perianal Crohn’s disease (pCD), the most debilitating manifestation of the inflammatory bowel ...

Left untreated, PNH could cause death in about half of patients within 10 years of diagnosis. The primary cause of PNH-related mortality is thromboembolic events. A host of anti-complement strategies, ...

Atypical haemolytic uremic syndrome (aHUS) is an uncommon, yet potentially life‐threatening disorder predominantly characterised by dysregulation of the alternative complement pathway. Unlike the more ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial (NCT06209177) of ARO-CFB, the ...

Cedars-Sinai investigators have identified a genetic variant that increases people's risk of developing perianal Crohn's disease, the most debilitating manifestation of Crohn's disease. Science X ...

4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of Pennsylvania Announces sCFH as payload for ...